Mark Froimson
Known title: DirectorCIK: 0001709050
Mark Froimson's purchase track record
Mark Froimson has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 8/12/2024 | PCRX | $16K | +42.4% | +112.4% | +13.5% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Transaction History
| PCRX | ▲ Buy | Grant | 6,405 | $0 | 6/10/2026 | View on chart |
| PCRX | ▼ Sell | Open Market | 500 | $11K | 3/17/2026 | View on chart |
| PCRX | ▲ Buy | Grant | 6,163 | $0 | 6/11/2025 | View on chart |
| PCRX | ▲ Buy | Open Market | 1,400 | $16K | 8/12/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 5,230 | $0 | 6/12/2024 | View on chart |
| PCRX | ▲ Buy | Grant | 1,775 | $0 | 6/14/2023 | View on chart |
| PCRX | ▲ Buy | Grant | 1,160 | $0 | 6/8/2022 | View on chart |
| PCRX | ▼ Sell | Open Market | 1,000 | $59K | 5/9/2022 | View on chart |
| PCRX | ▼ Sell | Gift | 400 | $0 | 12/17/2021 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 15, 2026
Viatris agrees to acquire Pacira BioSciences for $1.65 billion
Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.
Viatris agrees to acquire Pacira BioSciences for $1.65 billion. Viatris has announced plans to acquire Pacira BioSciences for $1.65 billion to expand its non-opioid pain management portfolio. Analysts from RBC and Truist have responded by raising their price targets to $36.50, though Truist downgraded the stock to Hold. The deal is seen as a significant move for Viatris, with RBC noting that a superior bid is unlikely.